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Abstract
Background: Disappointing results from clinical trials of disease-modifying interventions for Alzheimer’s dementia
(AD), along with reliable identification of modifiable risk factors in mid life from epidemiological studies, have
contributed to calls to invest in risk-reduction interventions. It is also well known that AD-related pathological
processes begin more than a decade before the development of clinical signs. These observations suggest that
lifestyle interventions might be most effective when targeting non-symptomatic adults at risk of AD. To date,
however, the few dementia risk-reduction programs available have targeted individual risk factors and/or were
restricted to clinical settings. The current study describes the development of an evidence-based, theoretically-
driven multidomain intervention to reduce AD risk in adults at risk.
Method: The design of Body Brain Life (BBL) is a randomized controlled trial (RCT) to evaluate a 12-week online AD
risk-reduction intervention. Eligible participants with several modifiable risk factors on the Australian National
University (ANU) AD Risk Index (ANU-ADRI) are randomly allocated to an online only group, an online and face-to-
face group, or an active control group. We aim to recruit 180 participants, to undergo a comprehensive cognitive
and physical assessment at baseline, post-intervention, and 6-month follow-up assessment. The intervention
comprises seven online modules (dementia literacy, risk factor education, engagement in physical, social, and
cognitive lifestyles, nutrition, and health monitoring) designed using contemporary models of health behavior
change.
Discussion: The BBL program is a novel online intervention to reduce the risk of AD in middle-aged adults at risk.
The trial is currently under way. It is hypothesized that participants in the intervention arms will make lifestyle
changes in several domains, and that this will lead to a reduction in their AD risk profile. We also expect to show
that health behavior change is underpinned by changes in psychological determinants of behavior. If successful,
the findings will contribute to the development of further dementia risk reduction interventions, and thus
contribute to the urgent need to lower dementia risk factors in the population to alter future projections of disease
prevalence. Longer follow-up of BBL participants and replications using large samples are required to examine
whether reduction in AD risk factors will be associated with reduced prevalence.
Trial registration: Reg. no. ACTRN12612000147886
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Background
As the most common cause of dementia, Alzheimer’s
disease (AD) affects approximately 35 million people
worldwide, and this will increase with population ageing
[1]. There is increasing focus on delaying the onset of
AD through intervening to modify risk factors [2,3], and
it has recently been estimated that a 10% to 25% reduc-
tion in 7 key risk factors could prevent 1.3 million AD
cases internationally [2]. To our knowledge only a few
prevention trials for Alzheimer’s disease are currently
under way, and interventions that could be delivered at
the population level (as opposed to interventions conduc-
ted in clinical settings) have not yet been developed. The
largest ongoing trial of dementia prevention is the Multi-
domain Alzheimer Prevention Trial (MAPT), which in-
volves MRIs, fish oil and clinical assessments, and costs
millions of dollars. Other randomized controlled trials
(RCTs) targeting dementia prevention have either focused
on a single risk factor (for example, hypertension) or are
clinically based and require full medical assessments and
expensive treatment regimes. There is an urgent need to
develop population-level, low-cost interventions that will
reduce the risk of AD.
The present study builds on our research program on
dementia risk reduction that commenced in 2005 and
has led to four systematic reviews [4-7], and the devel-
opment of evidence-based and validated self-report tool
for the assessment of risk of AD [8]. We have also
examined predictors of conversion to preclinical demen-
tia in our PATH Project [9]. We have designed an inter-
vention study to reduce the risk of AD by concurrently
targeting modifiable risk factors in middle-aged adults.
The intervention is designed for distribution via the
Internet, and hence, may reach a far wider group of in-
dividuals within the population than the high-cost me-
dical interventions currently under way.
Risk factors for cardiovascular disease in older persons
are well established and include several modifiable life-
style factors. More recently, converging evidence from
large epidemiological studies has confirmed that some of
the central modifiable risk factors for cardiovascular dis-
ease are also risk factors for AD, the most common cause
of dementia in people over 65 years of age. These factors
include smoking, alcohol consumption, poor diet, depres-
sion, and physical inactivity. Other factors that appear to
play a protective role in the prevention of AD, such as en-
gagement in social and cognitively stimulating lifestyles,
may play less of a role in the prevention of cardiovascular
disease. The proposed trial (reg. no. ACTRN1261200014
7886) is currently under way in Australia.
Targeting mid-life adults at risk
To date, most interventions to reduce dementia risk have
generally targeted older individuals (>65 years), who are at
risk of AD due to the presence of objective or subjective
cognitive decline, a positive family history of dementia, or
the detection of disease biomarkers. However, it is widely
accepted now that pathological processes that lead to the
development of clinical AD commence years and even
decades before the onset of any detectable clinical symp-
toms [10]. It has been suggested that intervening at the
point at which clinical symptoms become apparent may
be too late. In addition, commencing in 2005, a series of
systematic reviews by our group has demonstrated the
links between several risk factors in mid life and the likeli-
hood of developing dementia later in life [4-7]. Building
on our findings and those of other groups, we have re-
cently developed and validated a self-reported measure of
AD risk at mid life [8]. Using such a tool in the develop-
ment of interventions to reduce the prevalence of demen-
tia risk factors in mid life may therefore have far-reaching
implications for the incidence of dementia in later life.
Use of behavior change theory
Although theory-driven interventions have been develo-
ped in the context of single risk factors to prevent car-
diovascular disease (see, for example, [11]), research into
dementia that concurrently targets various risk factors is
in its infancy. Existing interventions have not been expli-
citly developed against a clear theoretical framework of
behavior change. However, there is evidence that lifestyle
interventions informed by theoretically-driven behavior
change models are more successful and lead to stronger
and more lasting changes [12]. Consequently, a complex
intervention based on an emerging theoretical and em-
pirical model of health-related behavior change [13-15]
has been developed for the current project.
Online delivery
The percentage of interventions developed and delivered
over the Internet has grown dramatically over the past
decade. Internet-delivered interventions are appealing to
public health professionals for several reasons. First and
most importantly, online interventions provide the op-
portunity for large-scale implementation at the popula-
tion level compared with more traditional face-to-face
interventions. Further, although the initial cost associa-
ted with setting up such interventions is at times rela-
tively high, their cost effectiveness lies in the relatively
small ongoing costs, which coupled with their wide
reach has the potential of having large impact [16].
Finally, the ever-increasing sophistication of Internet-
based health interventions enables them to become indi-
vidually tailored [17]. Evidence has emerged in recent
years of the effectiveness of online health interventions
in changing behavior including smoking and alcohol use
[18-20], and it is likely that in the years to come this will
become a primary mode of intervention delivery. To our
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knowledge, however, there are no existing interventions
to reduce the risk of AD delivered over the Internet.
Methods
Study setting and design
The BBL project is a 12-week, single-blind randomized
control trial of a behavior change intervention targeting
established risk factors for AD delivered to cognitively
healthy adults aged 50 to 60 either exclusively online or
as a combination of online and small group meetings.
These two groups are being compared to an active con-
trol group receiving weekly email links to relevant health
information. The study is being conducted in Canberra,
Australia.
Participants
Recruitment for this study is currently ongoing. Par-
ticipants are being recruited from the community via ad-
vertising in local newspapers and radio, as well as by
distributing fliers in community health centers, com-
munity clubs, and through word of mouth. Participants
who call the study number are added to a database of
those expressing an interest in the study. Potential
participants are then contacted by phone or email and
are provided with additional details regarding the study
and with a brief set of questions to establish whether
basic inclusion criteria (see below) are met. Participants
are also asked at this point to consent to undergo fur-
ther screening in the form of two brief phone interviews
to further establish the presence of inclusion or exclu-
sion criteria.
Inclusion criteria
Study prerequisites are that participants are aged 50 to
60, reside in the Australian Capital Territory or sur-
rounding areas of New South Wales, have access to a
computer and Internet connection at home, and are flu-
ent in English. To be eligible for the study, participants
are required to meet a minimum of three of the fol-
lowing risk factors for AD: formal educational attain-
ment at high-school level or less, sedentary lifestyle,
overweight or obese body mass index (BMI), low con-
sumption of fish, low cognitive or social engagement, as
well as a history of diabetes, hypertension, high choles-
terol, mild to moderate traumatic brain injury, smoking,
or depression. Participants are required to be able to at-
tend the Centre for Research on Ageing, Health, and
Wellbeing at baseline and after 24 weeks for face-to-face
evaluations.
Exclusion criteria
Participants are not eligible to enroll in the trial if they
have a history of neurological or psychiatric conditions
likely to substantially affect cognition (for example, recent
stroke, epilepsy, schizophrenia), sensory deficits or mo-
bility limitations that would prevent or substantially re-
strict the delivery of the assessment or intervention (for
example, uncorrected substantial loss of hearing or vision,
severe physical disability), as well as other significant
health problems (for example, recent cardiovascular
event, renal failure, treatment for cancer). Participants
are also required to obtain a score greater than 24 on
the TELE instrument (a phone-based assessment of men-
tal status) [21] to exclude the presence of global cognitive
impairment.
Phone interviews
Two brief phone interviews conducted by research as-
sistants with graduate psychology training using a writ-
ten protocol are being conducted with participants as
part of the screening process. The first interview focuses
on past and present medical conditions that form the
study’s inclusion and exclusion criteria, while the second
interview focuses on lifestyle factors. Each of the phone
interviews generally lasts approximately 10 minutes.
Sample size calculations
Sample size calculations were estimated using G*Power
(version 3.1.3)(Available at: University of Dusseldorf
available at http://www.psycho.uni-duesseldorf.de/aap/
projects/gpower/.) and were based on medium effect
sizes found for multidomain lifestyle interventions for
the primary prevention of cardiovascular disease (CVD)
[22] due to the lack of published trials on dementia risk
reduction. To detect a medium effect in a 3-group de-
sign (1:1:1), with a 5% risk of type 1 error (α) and 80%
power, a total sample size of 159 persons is required. A
medium effect (0.5 standard deviation) on the Australian
National University AD Risk Index (ANU-ADRI) is 4.25
points on the scale as described previously [8]. This fig-
ure is derived from the pooled standard deviation of the
ANU-ADRI from three cohort studies with combined N
of 4301; the Rush Memory and Aging Study, the
Kungsholmen Project, and the Cardiovascular Health
Study. To account for attrition, a baseline sample of 180
is being recruited.
Assessments
Table 1 summarizes the primary and secondary assess-
ment measures and the assessment schedule.
Primary outcome
The primary outcome measure is the ANU-ADRI [8].
The ANU-ADRI was developed following a synthesis of
meta-analyses of various risk factors for AD reported in
the literature. The questionnaire covers several modifi-
able risk factors and is based on self-report.
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Secondary outcomes
Domain-specific psychological determinants question-
naires: For each intervention domain, a questionnaire
was developed evaluating 14 empirically-derived theoret-
ical determinants of behavior [23]. Changes in psycho-
logical determinants of behavior are hypothesized to
underpin lifestyle changes. Domain-specific question-
naires are completed at the start of each behavior-
change module, and are then used to tailor the content
of online modules to the needs of individual participants.
Domain-specific questionnaires will be readministered
as part of the post-intervention assessment (12 weeks).
Dementia literacy [24]: this is assessed using a measure
developed by the authors at the baseline, immediate
post-intervention, and follow-up assessments.
Cognitive assessment: the cognitive evaluation inclu-
des the administration of several commonly used measu-
res of cognitive ability, including measures of estimated
intellectual ability, information processing speed, atten-
tion, memory, and executive function. These measures
are administered as a combination of paper-and-pencil
tests, and online via the trial website (Table 1).
Physical assessment: the physical evaluation includes
the assessment of lung capacity measured with a spirom-
eter (yielding forced expiratory volume and forced vital
capacity), blood pressure (measured twice for increased
reliability), knee extension (quadriceps strength), height,
weight, and waist circumference.
Blood measures (optional): participants who consent
to the blood test are referred to a central agency in
Canberra (Capital Pathology) for blood collection. The
following tests are requested: Fasting blood glucose, cho-
lesterol, triglycerides, full blood count, liver function,
renal function, and hemoglobin HbA1c. In addition,
plasma is being separated and stored using standard pro-
cedures, in order to examine AD blood biomarkers at a
later date. Participants who consent to the blood test are
asked to provide the details of their general practitioner
(GP), and all copies of the blood test results are for-
warded to the nominated GP after being received by the
study team.
Interventions
Group 1: BBL online only (BBL)
Participants in the online only group log on to the trial
website weekly to complete an online session lasting
approximately 1 h. The 12-week program is detailed
in Table 2. The first 7 weeks include the completion
of seven educational and individually-tailored behavior-
change modules. In the remaining 5 weeks, participants
undertake online activities focused on activity and goal
monitoring and revision. Tailoring of the five behavior-
change modules (weeks 3 to 7) is conducted using an
automated algorithm that presents content on the basis
of whether or not the particular risk factor the module
addresses applies to the participants, as well as on the
basis of their responses to several questions measuring
psychological determinants of behavior which are pre-
sented at the beginning of each of the behavior-change
modules. For example, a person who is classified as sed-
entary on the basis of their responses on the ANU-
ADRI, and who does not regard himself/herself as opti-
mistic regarding their prospect of change in the area of
physical activity, is presented with information about
learned optimism and the relationship between opti-
mism and a range of health outcomes. A physically
Table 1 Assessment measures at the baseline,
post-intervention, and follow-up evaluations
Assessment measure Baseline 12 weeks 24 weeks
Questionnaires
ANU-ADRIa X X X
Dementia literacy questionnairea X X X
Motivation questionnairea X X X
Cognitive measures
Logical memory X X
RAVLT X X
RCFT X X
COWAT (FAS) X X
Category fluency (animals, boys,
category switching)
X X
WTAR X X
Digit span X X
Digit-symbol matchinga X X
Trials A + Ba X X
Physical evaluation
Blood pressure X X
Height, cm X X
Weight, kg X X
Hip to waist ratio X X
Forced expiratory volume X X
Forced vital capacity X X
Quadriceps strength X X
Blood tests (optional)
Lipids X X
ALT X X
HbA1c X X
Renal function X X
aAdministered online on the trial website.
ALT, alanine aminotransferase; ANU-ADRI, Australian National University
Alzheimer’s Disease Risk Index; COWAT, Controlled Oral Word Association Test;
Hb, hemoglobin; RAVLT, Rey Auditory Verbal Learning Test; RCFT, Rey Complex
Figure Test; WTAR, Wechsler Test of Adult Reading.
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active person who also regards himself/herself as a role
model to others in the area of physical activity will not
be presented with information focusing on becoming a
role model to others.
The program is built in such a way that participants
are only able to access the relevant component of the
intervention at a given time. The modules become ac-
tive, one per week, on the same day for the first 7 weeks.
Participants are unable to access a newly activated mod-
ule before completing the previously scheduled module.
Each week, participants receive a notification email on
the same day alerting them when a new module has be-
come active. The automatic notification system on the
trial website is able to detect whether a given participant
has not commenced, commenced but not completed, or
completed a particular module, and the weekly messages
are modified accordingly. Participants receive up to two
automatic reminders to complete a module, and this is
then followed by a text message, before phone contact is
initiated by the study team. As per participation consent
agreements, participants who fail to complete a module
after these attempts are excluded from the study.
Group 2: BBL online + face-to-face (BBL + FF)
This group participates in the online program in the
same way as group 1, and in addition attends five face-to-
face sessions conducted in small groups facilitated by
a clinical psychologist (weeks 3, 5, 7, 9 and 12). The
content of the group sessions is organized around the
themes of the corresponding online modules. The ses-
sions include facilitated discussions of the various risk
factors for dementia, goal setting, and barriers to behav-
ior change. To monitor and evaluate fidelity of delivery,
the sessions are pre-scripted and a subset is recorded
and are subsequently analyzed.
Contact with participants in this group is similar to the
contact made with participants in the online only group
(that is, using the automated website notification system),
with the exception that participants in this group also
receive additional emails to remind them of upcoming
face-to-face sessions. As there is a single intervention-
ist (clinical psychologist) conducting the face-to-face
groups, we will not address interventionist performance
variability in the analysis.
Group 3: Active control (ACON)
The active control group does not access the trial web-
site. Instead, participants in this group receive weekly
emails containing links to health-related websites, vid-
eos, news items, and so on. The weekly emails contain
several links, and participants are encouraged to spend
an hour each week browsing through the material. The
Table 2 Description of the 12-week online program delivered through the Body Brain Life (BBL) trial website
Week Activity Description
1 Module 1: Dementia literacy The first module focuses on providing participants with general information about dementia
including types, onset, symptoms, diagnosis, progression, burden and risk factors (modifiable
and non-modifiable). This module serves as an introduction to the subsequent modules.
2 Module 2: Dementia risk factors This module is aimed at building awareness and knowledge of the various health conditions
associated with an increased risk of Alzheimer’s dementia (AD). Specifically, this module provides
details regarding the association between AD and several medical conditions (abnormal weight,
high cholesterol, diabetes, hypertension, and depression), as well as lifestyle factors (physical
activity, nutrition, social and cognitive engagement).
3 Module 3: BBL FIT - physical activity This is a theory-driven, individually-tailored module that aims to help participants incorporate
regular physical activity into their daily routine and reduce sedentary behavior. This module
targets several risk factors concurrently, including sedentary lifestyle, abnormal weight, depression,
and various medical conditions.
4 Module 4: BBL nutrition This is a theory-driven, individually-tailored module aimed at helping people develop healthy
dietary habits. This module targets the risk associated with abnormal weight, and the protective
effects associated with fish intake and with other dietary components.
5 Module 5: BBL connect - social
engagement
This is a theory-driven, individually-tailored module aimed at increasing participants’ levels of social
engagement. The module targets the risk factor for dementia associated with depression, and the
protective effects of regular social engagement.
6 Module 6: BBL Think - cognitive
engagement
This is an individually-tailored module aimed at increasing participants’ levels of engagement with
mentally stimulating activities, which is a protective factor against dementia.
7 Module 7: BBL health self-management This is an individually-tailored module aimed at increasing participants’ health monitoring and
management of chronic health conditions. Because several chronic health conditions are associated
with increased risk for dementia, prevention and appropriate management of such conditions is also
likely to be protective against dementia.
8 to 12 Self-guided online activities During these sessions, participants are encouraged to engage in a range of online activities for 1 h,
including accessing the many tools they have accumulated during the first 7 weeks. Examples
include the goal-setting tool, behavior-monitoring tool, unhelpful thoughts monitoring tool, videos,
and so on.
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material is generally organized around the same themes
as the ones included in the online BBL program. An ef-
fort has been made to include links to informational and
educational material but that otherwise does not include
the use of identifiable behavior-change techniques which
are the ‘active ingredient’ of the BBL program (for exam-
ple, vicarious reinforcement, anticipated regret, and so
on). In addition, other than providing participants with
the weekly emails, no further contact is made with the
participants in this group, such as reminders and prompts
that are delivered to participants in the two experimental
groups.
Randomization
A permuted block randomization sequence comprising
block sizes of 30 stratified by gender is used. The alloca-
tion sequence is generated by an independent researcher
following the baseline assessments and is not known to
the study team at the time of enrollment and baseline
assessment.
Blinding
To prevent evaluation bias, research staff conducting the
psychological, physical, and cognitive outcome assess-
ments, as well as those involved in the analysis of path-
ology data remain blind to participants’ group allocation.
The contact person for participants’ website queries, ac-
cess issues, and technical difficulties is independent of
all baseline assessment data. All participants are infor-
med that they are being randomly allocated to one of
three study groups and that one group may be more ef-
fective than others. They are also notified at the start of
the study that one of these groups involves several face-
to-face sessions. Hence, participants in the two online
groups are kept blinded to group allocation, whereas those
allocated to the online + face-to-face group are naturally
able to tell the group they have been allocated to.
Statistical analyses
Statistical analyses will be based on an intention-to-treat
approach. Recent commentary on the best practice for
dealing with missing data in RCTs suggests that multiple
imputation and Mixed Models are effective approaches
and superior to the commonly used techniques like ‘last
observation carried forward’ for missing data [25,26].
We plan to use Mixed Models. We hypothesize that
BBL + FF > BBL > ACON. The hypothesis that BB +
FF > BBL is based on research [27] showing that social
milieu and personal contact with researchers are associa-
ted with better outcomes in online interventions. There
is no empirical evidence on which to base the hypothesis
that BBL + FF > BBL in relation to dementia risk reduc-
tion per se, due to lack of published data. Results will be
exploratory because there are no previous findings in
the literature to confirm. There is random allocation to
groups so we do not plan to adjust for baseline variables
in the primary analysis. In sub analyses we will adjust for
baseline measures such as compliance in completing the
online modules (in the BBL and BBL + FF groups) by in-
cluding the number of online modules completed as a
fixed effect.
Ethics
The Human Research Ethics Committee at the Australian
National University has approved the study protocols and
procedures.
Adverse events
This study evaluates a lifestyle intervention program to
reduce risk factors for AD. The target population is
adults in mid life who have some of the known risk
factors for dementia, but are at the time of the interven-
tion healthy and free of any dementia-related symptoms.
We do not anticipate that participants will be placed at a
greater risk than that associated with self-driven educa-
tional activities over the Internet. Results of screening
blood tests are sent to participants’ primary health care
providers regardless of their group designation. Further-
more, if any abnormality is detected, a letter is sent to
participants to inform them of the presence of the ab-
normal result and encouraging them to contact their
general practitioner for medical advice. To address is-
sues of potential fatigue, the baseline assessment has
been kept to a minimum length. In addition, all online
and face-to-face sessions were designed in an interactive
way and are limited to 1-h sessions (90 minutes for the
face-to-face groups). As mentioned above, all online
modules are delivered in an individually-tailored fashion
to maximize relevance for each individual.
Discussion
The BBL project is currently under way as an evaluation
of the efficacy of a novel intervention in a randomized
control trial design. The design of the BBL program
aimed to overcome some of the central limitations of
similar intervention efforts to date by primarily using a
validated AD risk assessment tool, by targeting indivi-
duals at late mid life, by developing the intervention
content against sound theoretical background, and by
choosing an individually-tailored, online delivery format.
The trial, advertised through local radio and newspa-
pers, community clubs, health centers, and noticeboards,
generates considerable interest, and to date, approxi-
mately one-third of the total target sample has been
assessed and randomized into the intervention groups.
We anticipate that recruitment will continue until March
2013, and it is estimated that all data collection will be
complete by September 2013. The trial has been designed
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against the Consolidated Standards of Reporting Trials
(CONSORT) reporting guidelines [28], and the results of
the study are likely to form an evidence base for the feasi-
bility of dementia-prevention campaigns to lead to lifestyle
changes and the reduction of dementia risk factors at the
population level.
The positive response to the study from individuals
who traditionally do not see themselves as the target
population for dementia-related studies, most of whom
are still in the workforce, reflects community concern
regarding dementia risk, and an interest in emerging
prevention efforts. Therefore, successful outcomes of the
current trial may be associated with actual public health
impact upon making the intervention available at the
population level. Although additional funds are likely to
be required to update and improve aspects of the online
intervention program, a particularly strong appeal of this
intervention is the fully automated yet individually-
tailored online delivery, with negligible maintenance costs.
The study has some limitations. The relatively small
sample size limits the possibility of designing more than
one control condition, and reduces the feasibility of mean-
ingful long-term follow-up. The study will be under-
powered to evaluate the effect (if any) of group within the
BBL + FF condition, and this potentially limits the non-
independence of the participants. Exploratory analyses of
this effect will still be conducted. The project is, however,
a pilot project, and the outcome data will form the basis
for an application for funding for a larger scale trial. Fi-
nally, as is the case for other intervention trials recruiting
healthy volunteers, the sample may not adequately re-
present the general population of those at risk of AD.
However the inclusion criteria requiring three or more
risk factors mitigates this to some extent. Ongoing
efforts are being made to recruit individuals from di-
verse backgrounds.
Conclusions
Interventions to prevent or delay the onset of clinical
AD and other dementia are urgently needed, and global
efforts are beginning to shift in this direction. The BBL
trial provides a novel approach to addressing this pres-
sing public health burden.
Trial status
The trial is ongoing.
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